[go: up one dir, main page]

MX2018012651A - Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies. - Google Patents

Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies.

Info

Publication number
MX2018012651A
MX2018012651A MX2018012651A MX2018012651A MX2018012651A MX 2018012651 A MX2018012651 A MX 2018012651A MX 2018012651 A MX2018012651 A MX 2018012651A MX 2018012651 A MX2018012651 A MX 2018012651A MX 2018012651 A MX2018012651 A MX 2018012651A
Authority
MX
Mexico
Prior art keywords
ctla
compositions
coformulation
antibodies
antibody
Prior art date
Application number
MX2018012651A
Other languages
Spanish (es)
Inventor
Shah Ambarish
Du Jiali
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2018012651A publication Critical patent/MX2018012651A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Provided herein are compositions comprising coformulation of anti-PD-Ll and anti-CTLA-4 antibodies, or antigen-binding fragments thereof, and methods of making and using such compositions. In various aspects, stable coformulations of the anti-PD-Ll antibody durvalumab (MEDI4736) and the anti-CTLA-4 antibody tremelimumab are provided.
MX2018012651A 2016-04-25 2017-04-24 Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies. MX2018012651A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662327214P 2016-04-25 2016-04-25
PCT/US2017/029143 WO2017189433A1 (en) 2016-04-25 2017-04-24 Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies

Publications (1)

Publication Number Publication Date
MX2018012651A true MX2018012651A (en) 2019-01-30

Family

ID=60089975

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012651A MX2018012651A (en) 2016-04-25 2017-04-24 Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies.

Country Status (19)

Country Link
US (2) US10421811B2 (en)
EP (1) EP3448428A4 (en)
JP (1) JP2019514889A (en)
KR (1) KR20180135475A (en)
CN (1) CN109069631A (en)
AR (1) AR108317A1 (en)
AU (1) AU2017257505B2 (en)
BR (1) BR112018071287A2 (en)
CA (1) CA3020893A1 (en)
CL (1) CL2018002998A1 (en)
CO (1) CO2018011195A2 (en)
IL (1) IL262344A (en)
MA (1) MA44783A (en)
MX (1) MX2018012651A (en)
RU (1) RU2018140960A (en)
SG (1) SG11201807474SA (en)
TW (1) TW201740976A (en)
WO (1) WO2017189433A1 (en)
ZA (1) ZA201807888B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20151102T1 (en) * 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. HUMAN MONOCLONAL ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
KR20240056664A (en) 2013-09-11 2024-04-30 메디뮨 리미티드 Anti-b7-h1 antibodies for treating tumors
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp TIM-3 Antibody Molecules and Their Uses
RS59853B1 (en) 2014-03-14 2020-02-28 Novartis Ag Antibody molecules to lag-3 and uses thereof
US10232040B2 (en) * 2014-05-13 2019-03-19 Medimmune, Llc Anti-B7 H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
KR20170060042A (en) 2014-09-13 2017-05-31 노파르티스 아게 Combination therapies of alk inhibitors
TWI716362B (en) 2014-10-14 2021-01-21 瑞士商諾華公司 Antibody molecules to pd-l1 and uses thereof
MX2017011644A (en) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof.
BR112018011781A2 (en) 2015-12-14 2018-12-04 Macrogenics, Inc. bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
CN108350082B (en) 2016-06-13 2021-09-24 天境生物科技(上海)有限公司 PD-L1 antibody and its use
CA3052652A1 (en) * 2017-02-16 2018-08-23 John KURLAND Anti-pd-l1 antibody treatment of bladder cancer
WO2018204405A1 (en) * 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
BR112019025188A2 (en) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. ACTIVABLE ANTI-PDL1 ANTIBODIES AND METHODS OF USE OF THE SAME
EP3630180A1 (en) 2017-06-01 2020-04-08 Compugen Ltd. Triple combination antibody therapies
KR20210005096A (en) * 2018-04-25 2021-01-13 메디뮨 리미티드 Formulation of human anti-PD-L1 antibody
WO2020020307A1 (en) 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
CA3203441A1 (en) * 2020-12-30 2022-07-07 Jing Zhu Formulations of anti-cd73 antibodies
EP4611898A1 (en) * 2022-11-04 2025-09-10 Astrazeneca AB Anti-ctla antibody compositions and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2620450T (en) * 2005-03-08 2018-12-17 Pfizer Prod Inc Anti-ctla-4 antibody compositions
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
SMT202500126T1 (en) * 2008-12-09 2025-05-12 Hoffmann La Roche Anti-pd-l1 antibodies and their use to enhance t-cell function
HRP20171653T1 (en) * 2009-11-24 2017-12-15 Medimmune Limited Targeted binding agents against b7-h1
CN107496917B (en) * 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 Compositions comprising stable antibodies
EP2794653B1 (en) 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
US10232040B2 (en) * 2014-05-13 2019-03-19 Medimmune, Llc Anti-B7 H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
WO2016030455A1 (en) * 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
DK3209778T3 (en) * 2014-10-24 2019-05-27 Astrazeneca COMBINATION
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia

Also Published As

Publication number Publication date
CL2018002998A1 (en) 2018-12-07
WO2017189433A1 (en) 2017-11-02
IL262344A (en) 2018-11-29
US20170306025A1 (en) 2017-10-26
AU2017257505B2 (en) 2020-05-14
CN109069631A (en) 2018-12-21
EP3448428A4 (en) 2019-11-27
CA3020893A1 (en) 2017-11-02
US20190382494A1 (en) 2019-12-19
SG11201807474SA (en) 2018-11-29
AR108317A1 (en) 2018-08-08
US10421811B2 (en) 2019-09-24
JP2019514889A (en) 2019-06-06
MA44783A (en) 2019-03-06
RU2018140960A3 (en) 2020-08-03
EP3448428A1 (en) 2019-03-06
TW201740976A (en) 2017-12-01
AU2017257505A1 (en) 2018-12-06
RU2018140960A (en) 2020-05-26
KR20180135475A (en) 2018-12-20
ZA201807888B (en) 2019-08-28
BR112018071287A2 (en) 2019-02-19
CO2018011195A2 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
MX2018012651A (en) Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies.
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
SG10201901057UA (en) Anti-pd-l1 antibodies
IL269336B2 (en) Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2022015823A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof.
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
IL291545B2 (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
ZA202102034B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
MY188940A (en) Anti-pd-l1 antibodies and diagnostic uses thereof
WO2016014688A3 (en) Anti-pd-1 antibodies
CR20180480A (en) CHEMICAL RECEPTORS AND METHODS OF USE OF THE SAME
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
IL273484A (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
PH12018502502A1 (en) Anti-gitr antibodies and uses thereof
WO2018031490A3 (en) Anti-ox40 binding proteins
WO2018069871A3 (en) Anti-kras binding proteins
EP3778635A4 (en) Anti-pd-l1 antibody and use thereof
NZ729395A (en) Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
MX2018009218A (en) Cgrp antibodies and uses thereof.